Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. DLR
2. EOSE
3. AVAV
4. VSH
5. ENPH
6. CMCSA
7. CNXC
8. SPY
9. MAMA
10. ABVX

Go back to Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data

Sangamo Therapeutics (SGMO) Continues to Gain, Now Up 50%

April 2, 2019 8:39 AM EDT

Sangamo Therapeutics (NASDAQ: SGMO) Continues to Gain, Now Up 50%

... More

Sangamo Therapeutics (SGMO) Hits Pre-Market High, Up 26%

April 2, 2019 8:09 AM EDT

Sangamo Therapeutics (NASDAQ: SGMO) Hits Pre-Market High, Up 26%

... More